Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.56 |
| ▸ | PRCP | P42785 | 1/20 | 0.56 |
| ▸ | CD44 | P16070 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801575 | 1.00 | PNMT (0.56) | PNMTPRCPCD44MAOBADRA2A | |
| Hydrochloric Acid SCHEMBL17822916 | 0.98 | PNMT (0.54) | PNMTPRCPCD44MAOBADRA2A | |
| SCHEMBL30744757 | 0.88 | CD44 (0.54) | PNMTPRCPCD44MAOB | |
| SCHEMBL2329950 | 0.88 | CD44 (0.54) | PNMTPRCPCD44MAOB | |
| SCHEMBL15569496 | 0.86 | PNMT (0.53) | PNMTPRCPCD44MAOB | |
| SCHEMBL29800858 | 0.86 | PNMT (0.53) | PNMTPRCPCD44MAOB | |
| SCHEMBL6840295 | 0.86 | PNMT (0.53) | PNMTPRCPCD44MAOB | |
| SCHEMBL29662964 | 0.85 | ALDH1A1 (0.43) | PNMTPRCPCD44 | |
| SCHEMBL1817879 | 0.85 | ALDH1A1 (0.43) | PNMTPRCPCD44 | |
| Hydrochloric Acid SCHEMBL2494227 | 0.85 | PNMT (0.51) | PNMTPRCPCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107778230-A | A kind of synthetic method of tetrahydro isoquinoline derivative | 湖南华腾制药有限公司 | 2018-03-09 | — | — | CN | claimed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| CN-103788084-A | Tetrahydroisoquinoline derivative and synthesis method thereof | Hunan huateng pharmaceutical co ltd | 2014-05-14 | — | — | CN | claimed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | claimed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240115725-A1 | Anti-EGFR Antibody-Drug Conjugates | ABBVIE INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4281117-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | AbbVie Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159576-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | ABBVIE INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-109311843-B | Azabenzimidazole derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2021-10-08 | — | — | CN | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| CN-103987711-A | 8-carbamoyl-2- (2, 3-disubstituted pyridin-6-yl) -1,2,3, 4-tetrahydroisoquinoline derivatives as apoptosis inducers for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC | 2014-08-13 | — | — | CN | disclosed |
| CN-103958508-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC | 2014-07-30 | — | — | CN | disclosed |
| CN-103788084-A | Tetrahydroisoquinoline derivative and synthesis method thereof | Hunan huateng pharmaceutical co ltd | 2014-05-14 | — | — | CN | disclosed |
| WO-2014066490-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2010101230-A1 | QUINOXALINE COMPOUNDS | アステラス製薬株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115725-A1 | Anti-EGFR Antibody-Drug Conjugates | EGFR, ERBB2, ERBB3 | PNMT 4598/4885PRCP 730/4885CD44 41/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | PNMT 4782/4885PRCP 1311/4885CD44 187/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | PNMT 1536/4885PRCP 3932/4885CD44 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.